{
    "eid": "2-s2.0-85129080951",
    "title": "Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data",
    "cover-date": "2022-05-20",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Molecular Medicine",
            "@code": "1313",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Immunology and Microbiology (all)",
            "@code": "2400",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Veterinary (all)",
            "@code": "3400",
            "@abbrev": "VETE"
        },
        {
            "@_fa": "true",
            "$": "Public Health, Environmental and Occupational Health",
            "@code": "2739",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "AZD1222",
        "CoronaVac",
        "COVID-19",
        "Heterologous",
        "Vaccine"
    ],
    "authors": [
        "Nasamon Wanlapakorn",
        "Nungruthai Suntronwong",
        "Harit Phowatthanasathian",
        "Ritthideach Yorsaeng",
        "Thanunrat Thongmee",
        "Preeyaporn Vichaiwattana",
        "Chompoonut Auphimai",
        "Lakkhana Wongsrisang",
        "Sirapa Klinfueng",
        "Natthinee Sudhinaraset",
        "Yong Poovorawan"
    ],
    "citedby-count": 10,
    "ref-count": 24,
    "ref-list": [
        "Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial",
        "CombiVacS Study Group. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial",
        "Com-COV Study Group. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data",
        "Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination",
        "Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study",
        "A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18\u201359 years: An interim analysis in Indonesia",
        "Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",
        "Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study",
        "Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials",
        "Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection",
        "Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK",
        "COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants",
        "Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant",
        "Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand",
        "Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans",
        "Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial",
        "Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial",
        "Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals",
        "A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Dusit",
            "@id": "127564353",
            "affilname": "FRS(T)",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/127564353",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "King Chulalongkorn Memorial Hospital",
        "Chulalongkorn University",
        "National Research Council of Thailand",
        "Health Systems Research Institute"
    ]
}